Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (NCT04150887)

🧪 Interventions in This Study

• Cusatuzumab (DRUG)
• Azacitidine (DRUG)
• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• City of Hope — Duarte, California
• Norton Cancer Institute — Louisville, Kentucky
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
• Roswell Park Cancer Institute — Buffalo, New York
• Weill Cornell Medicine — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• University of Rochester — Rochester, New York
• University of Pittsburgh School of Medicine — Pittsburgh, Pennsylvania
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• University of Vermont — Burlington, Vermont
• Wisconsin Medical Center — Milwaukee, Wisconsin
• Tom Baker Cancer Centre — Calgary, Alberta
• University of Alberta Hospital — Edmonton, Alberta
• University of Toronto — Toronto, Ontario
• McGill University Health Centre — Montreal, Quebec
• Universitaetsklinik Hamburg-Eppendorf — Hamburg,
• Universitaetsklinikum Leipzig — Leipzig,
• Klinikum der Universitaet Muenchen — München,
• Szpital Uniwersytecki w Krakowie — Krakow,
• Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi — Lodz,
• Instytut Hematologii i Transfuzjologii — Warsaw,
• INSELSPITAL, Universitätsspital Bern — Bern,
• Kantonsspital St.Gallen — Sankt Gallen,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Leukemia, Myeloid, Acute

• A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — Gilbert, Arizona
• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy — Duarte, California
• A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies — Birmingham, Alabama
• A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms — Calgary, Alberta
• Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) — Houston, Texas

Explore by condition: All Leukemia, Myeloid, Acute clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.